Metabolon | Jotup

Metabolon Secures $25 Million of Funding to Accelerate Growth

Retrieved on:

Tuesday, January 24, 2023

Metabolomics, Biomarker, DNA, Protein, CFO, Growth, Genomics, Proteomics, Biology, Systems biology, Medicine, Research, Pharmaceutical industry, Metabolon

The proceeds will be used for general corporate purposes, helping Metabolon further accelerate commercialization activities and continue advancing its well-defined R&D roadmap.

Key Points:

The proceeds will be used for general corporate purposes, helping Metabolon further accelerate commercialization activities and continue advancing its well-defined R&D roadmap.
"Metabolon is experiencing significant growth, and we are excited to continue building our talented team and scaling our capabilities to meet increasing demand," said Rohan (Ro) Hastie, Metabolon's Chief Executive Officer.
As life sciences evolve toward a more sophisticated multi-omics approach, Metabolon is fast becoming an industry standard and a critical step toward true precision medicine."
To learn more about how Metabolon deciphers thousands of discrete chemical signals from genetic and non-genetic factors to discover biomarkers and reveal biological pathways, visit https://www.metabolon.com/ .

Metabolon Secures $25 Million of Funding to Accelerate Growth

Retrieved on:

Tuesday, January 24, 2023

Metabolomics, Biomarker, DNA, Protein, CFO, Growth, Genomics, Proteomics, Biology, Systems biology, Medicine, Research, Pharmaceutical industry, Metabolon

The proceeds will be used for general corporate purposes, helping Metabolon further accelerate commercialization activities and continue advancing its well-defined R&D roadmap.

Key Points:

The proceeds will be used for general corporate purposes, helping Metabolon further accelerate commercialization activities and continue advancing its well-defined R&D roadmap.
"Metabolon is experiencing significant growth, and we are excited to continue building our talented team and scaling our capabilities to meet increasing demand," said Rohan (Ro) Hastie, Metabolon's Chief Executive Officer.
As life sciences evolve toward a more sophisticated multi-omics approach, Metabolon is fast becoming an industry standard and a critical step toward true precision medicine."
To learn more about how Metabolon deciphers thousands of discrete chemical signals from genetic and non-genetic factors to discover biomarkers and reveal biological pathways, visit https://www.metabolon.com/ .

Metabolon Expands Inflammation Portfolio with Targeted Panels for Cannabinoids, Sphingolipids, and Lipid Mediators of Inflammation

Retrieved on:

Tuesday, January 17, 2023

MORRISVILLE, N.C., Jan. 17, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced a significant expansion of its Inflammation Portfolio with the launch of new Targeted Panels studying Cannabinoids, Sphingolipids, and Lipid Mediators of Inflammation. The Portfolio also includes the recently launched Oxysterols Targeted Panel. Metabolon's Inflammation Portfolio detects and provides deeper insights into a wide range of known bioactive mediators of inflammation for the prediction, early detection, and monitoring of disease states, including chronic pain, neuro-inflammatory disease, neurodegeneration, and cardiovascular diseases.

Key Points:

The Metabolon Sphingolipid Targeted Panel measures changes in 61 lipid species across five lipid classes with strong links to inflammation.
Lipid mediators of inflammation are a group of molecules involved in immune response and inflammation.
The balanced production and regulation of lipid mediators of inflammation are important for maintaining normal immune function and preventing chronic inflammation.
The Metabolon Lipid Mediators of Inflammation Targeted Panel detects 58 analytes associated with metabolic consequences of widespread inflammatory disease to identify biomarkers and their quantitative changes.

Metabolon Expands Inflammation Portfolio with Targeted Panels for Cannabinoids, Sphingolipids, and Lipid Mediators of Inflammation

Retrieved on:

Tuesday, January 17, 2023

MORRISVILLE, N.C., Jan. 17, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced a significant expansion of its Inflammation Portfolio with the launch of new Targeted Panels studying Cannabinoids, Sphingolipids, and Lipid Mediators of Inflammation. The Portfolio also includes the recently launched Oxysterols Targeted Panel. Metabolon's Inflammation Portfolio detects and provides deeper insights into a wide range of known bioactive mediators of inflammation for the prediction, early detection, and monitoring of disease states, including chronic pain, neuro-inflammatory disease, neurodegeneration, and cardiovascular diseases.

Key Points:

The Metabolon Sphingolipid Targeted Panel measures changes in 61 lipid species across five lipid classes with strong links to inflammation.
Lipid mediators of inflammation are a group of molecules involved in immune response and inflammation.
The balanced production and regulation of lipid mediators of inflammation are important for maintaining normal immune function and preventing chronic inflammation.
The Metabolon Lipid Mediators of Inflammation Targeted Panel detects 58 analytes associated with metabolic consequences of widespread inflammatory disease to identify biomarkers and their quantitative changes.

Metabolon Signs New Partnership with UK's Tracking Parkinson's Study

Retrieved on:

Tuesday, November 15, 2022

MORRISVILLE, N.C., Nov. 15, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced a new collaboration with Tracking Parkinson's, or the PRoBaND study, a UK-based longitudinal study of Parkinson's disease funded entirely by Parkinson's UK, to identify new metabolomic biomarkers and track biological changes over time to better understand Parkinson's disease pathogenesis.

Key Points:

Since 2012, Tracking Parkinson's has collected clinical data and biosamples from more than 2,500 participants, recruited into three categories including recent onset, early onset, and participant siblings.
The study tracks participants for seven years and is one of the most clinically phenotyped cohorts globally.
This collaboration will allow Metabolon and Tracking Parkinson's to map metabolic changes in serum to clinical changes and genetic variants related to Parkinson's disease, allowing for the identification of novel biomarkers of disease progression.
It is extremely rewarding after so many years of data collection to realize that ambition through collaborations with teams like Metabolon.

Metabolon Signs New Partnership with UK's Tracking Parkinson's Study

Retrieved on:

Tuesday, November 15, 2022

MORRISVILLE, N.C., Nov. 15, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced a new collaboration with Tracking Parkinson's, or the PRoBaND study, a UK-based longitudinal study of Parkinson's disease funded entirely by Parkinson's UK, to identify new metabolomic biomarkers and track biological changes over time to better understand Parkinson's disease pathogenesis.

Key Points:

Since 2012, Tracking Parkinson's has collected clinical data and biosamples from more than 2,500 participants, recruited into three categories including recent onset, early onset, and participant siblings.
The study tracks participants for seven years and is one of the most clinically phenotyped cohorts globally.
It is extremely rewarding after so many years of data collection to realize that ambition through collaborations with teams like Metabolon.
"We are extremely enthusiastic about partnering with Tracking Parkinson's to further the understanding of the pathogenesis of Parkinson's disease, said Karl Bradshaw, Vice President of Corporate Development at Metabolon.

Metabolon Advances the Understanding of Inflammation and Inflammatory Response with New Oxysterols Targeted Panel

Retrieved on:

Tuesday, October 25, 2022

MORRISVILLE, N.C., Oct. 25, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced the launch of its new Metabolon Oxysterols Targeted Panel that measures 12 oxysterols and related sterols of biological significance to identify biomarkers for the prediction and early detection of cardiovascular diseases, neurodegenerative diseases, and cancer.

Key Points:

Oxysterols, which are oxidized forms of cholesterol, can be formed enzymatically and non-enzymatically, in addition to being acquired from the diet.
However, identifying and measuring oxysterols can be challenging due to their low biological concentrations and structural similarity.
Through our fully developed Oxysterols Targeted Panel, we're excited to help our customers gain rapid insights into underlying biology and ultimately get closer to understanding and combating many major diseases," said Rangaprasad (Ranga) Sarangarajan, Ph.D., Chief Scientific Officer at Metabolon.
Over 20 years, 10,000+ projects, 2,800+ publications, and ISO 9001:2015 andCLIA certifications, Metabolon has developed industry-leading scientific, technology, and bioinformatics techniques.

Metabolon Advances the Understanding of Inflammation and Inflammatory Response with New Oxysterols Targeted Panel

Retrieved on:

Tuesday, October 25, 2022

MORRISVILLE, N.C., Oct. 25, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced the launch of its new Metabolon Oxysterols Targeted Panel that measures 12 oxysterols and related sterols of biological significance to identify biomarkers for the prediction and early detection of cardiovascular diseases, neurodegenerative diseases, and cancer.

Key Points:

Oxysterols, which are oxidized forms of cholesterol, can be formed enzymatically and non-enzymatically, in addition to being acquired from the diet.
However, identifying and measuring oxysterols can be challenging due to their low biological concentrations and structural similarity.
"Our world-class ISO 9001 laboratory has developed a quantitative assay to measure 12 sterols and oxysterols.
Over 20 years, 10,000+ projects, 2,800+ publications, and ISO 9001:2015 andCLIA certifications, Metabolon has developed industry-leading scientific, technology, and bioinformatics techniques.

Metabolon Partners with the Swedish BioFINDER 2 Study to Develop Biomarkers and Increase Insight into Alzheimer's and other Dementia Diseases

Retrieved on:

Tuesday, September 13, 2022

MORRISVILLE, N.C., Sept. 13, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced a partnership with the Swedish Biomarkers For Identifying Neurodegenerative Disorders Early and Reliably (BioFINDER) 2 Study. The partnership aims to develop novel metabolomic biomarkers, assist in the development of new pathology-based disease classifications, and investigate underlying disease mechanisms of dementia to help discover new relevant drug targets.

Key Points:

The Swedish BioFINDER 2 Study brings together leading scientists, universities, and companies worldwide and is designed to address issues related to the role of tau pathology in a broad spectrum of neurological diseases.
As part of the partnership, Metabolon will run metabolomics on both cerebrospinal fluid (CSF) and plasma from BioFINDER 2's baseline collections.
Metabolon and the Swedish BioFINDER 2 Study will also define the temporal evolution of pathologies in the pre-dementia phases of Alzheimer's.
"We are excited to collaborate with BioFINDER 2 to support early dementia disease research," said Ro Hastie, President & CEO of Metabolon.

Metabolon Partners with the Swedish BioFINDER 2 Study to Develop Biomarkers and Increase Insight into Alzheimer's and other Dementia Diseases

Retrieved on:

Tuesday, September 13, 2022

MORRISVILLE, N.C., Sept. 13, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced a partnership with the Swedish Biomarkers For Identifying Neurodegenerative Disorders Early and Reliably (BioFINDER) 2 Study. The partnership aims to develop novel metabolomic biomarkers, assist in the development of new pathology-based disease classifications, and investigate underlying disease mechanisms of dementia to help discover new relevant drug targets.

Key Points:

The Swedish BioFINDER 2 Study brings together leading scientists, universities, and companies worldwide and is designed to address issues related to the role of tau pathology in a broad spectrum of neurological diseases.
As part of the partnership, Metabolon will run metabolomics on both cerebrospinal fluid (CSF) and plasma from BioFINDER 2's baseline collections.
Metabolon and the Swedish BioFINDER 2 Study will also define the temporal evolution of pathologies in the pre-dementia phases of Alzheimer's.
"We are excited to collaborate with BioFINDER 2 to support early dementia disease research," said Ro Hastie, President & CEO of Metabolon.